// App-Quantinova.ai

: Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Researchers

Presenter

  • Al-Ola Abdallah

Principal Investigators

  • Andrew J Cowan

  • Xavier Leleu

  • Cyrille Touzeau

  • Brea Lipe

  • Eva Medvedova

  • Caitlin Costello

  • Jens Hillengass

  • P. Leif Bergsagel

  • Raya Mawad

  • Henning Schade

  • Daniel Morillo Giles

  • Albert Oriol

  • Yifah Yaron

  • Patrick P Ng

  • Sumit Madan

Medical Centers

  • Hematology Department, Nantes University Hospital, Nantes, France

  • Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ

  • Banner MD Anderson Cancer Center at Banner University Medical Center, Phoenix, AZ

  • Harpoon Therapeutics, South San Francisco, CA

  • Department of Oncology, Hematology and Cellular Therapy, Poitiers University Hospital, Poitiers, France

  • Department of Hematology, University Hospital Fundación Jiménez Díaz, Madrid, Spain

  • Institut Josep Carreras and Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain

  • University of California, San Diego, La Jolla, CA

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

  • Colorado Blood Cancer Institute, Denver, CO

  • Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS

  • Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY

  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA

  • Roswell Park, Buffalo, NY

Locations

  • France

  • United States

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Multiple Myeloma

  • Cytokine release syndrome

Biomarkers

  • Twist-related protein 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Safety

  • Fixed Dose

  • Multinational

  • Tolerability

  • Immunogenicity

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved